Elotuzumab therapy for relapsed or refractory multiple myeloma

Sagar Lonial, Meletios Athanasios Dimopoulos, Antonio Palumbo, Darrell J White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen, Andrew R Belch, Donna E Reece, Meral Beksac, Andrew Spencer, Heather Oakervee, Robert Z Orlowski, Masafumi Taniwaki, Christoph Rollig, Hermann Einsele, Ka Lung WuAnil Singhal, Jesus Fernando San Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt, Valerie Poulart, Kenneth Carl Anderson, Paul G Richardson

Research output: Contribution to journalArticleResearchpeer-review

1087 Citations (Scopus)


Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. Methods: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. Results: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68 , as compared with 57 in the control group; at 2 years, the rates were 41 and 27 , respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95 confidence interval, 0.57 to 0.85; P
Original languageEnglish
Pages (from-to)621 - 631
Number of pages11
JournalThe New England Journal of Medicine
Issue number7
Publication statusPublished - 2015

Cite this